Role of glucagon in catabolism and muscle wasting of critical illness and modulation by nutrition

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 9, 2017, Pages 1131-1143

  Thiessen, Steven E ^a   Derde, Sarah ^a   Derese, Inge ^a   Dufour, Thomas ^a   Vega, Chloe Albert ^a   Langouche, Lies ^a   Goossens, Chloe ^a   Peersman, Nele ^b   Vermeersch, Pieter ^b   Perre, Sarah Vander ^a   Holst, Jens J ^c,d   Wouters, Pieter J ^a   Vanhorebeek, Ilse ^a   Van Den Berghe, Greet ^a  

^a Department of Cellular and Molecular Medicine   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c NOVO NORDISK INC   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amino acids; Catabolism; Metabolism; Nutrition; Sepsis

Indexed keywords

AMINO ACID; GLUCAGON; GLUCOSE; INSULIN;

ADULT; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CATABOLISM; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; INFUSION; LIPID METABOLISM; LIVER INJURY; MACRONUTRIENT; MALE; MOUSE; MUSCLE ATROPHY; NONHUMAN; NUTRITIONAL SUPPORT; PARENTERAL NUTRITION; PRIORITY JOURNAL; SEPSIS; AGED; ANIMAL; BLOOD; DISEASE MODEL; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

AGED; AMINO ACIDS; ANIMALS; BLOOD GLUCOSE; CRITICAL ILLNESS; DISEASE MODELS, ANIMAL; FEMALE; GLUCAGON; GLUCOSE; HUMANS; INSULIN; MALE; MICE; MIDDLE AGED; MUSCULAR ATROPHY; PARENTERAL NUTRITION; TREATMENT OUTCOME;

EID: 85032667891     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201702-0354OC     Document Type: Article

References (47)

1. Hermans G, Casaer MP, Clerckx B, Güiza F, Vanhullebusch T, Derde S, Meersseman P, Derese I, Mesotten D, Wouters PJ, et al. Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. Lancet Respir Med 2013;1:621-629.
2. Gore DC, Jahoor F, Wolfe RR, Herndon DN. Acute response of human muscle protein to catabolic hormones. Ann Surg 1993; 218:679-684.
3. Preiser JC, Ichai C, Orban JC, Groeneveld AB. Metabolic response to the stress of critical illness. Br J Anaesth 2014;113:945-954.
4. Druml W, Heinzel G, Kleinberger G. Amino acid kinetics in patients with sepsis. Am J Clin Nutr 2001;73:908-913.
5. Casaer MP, Ziegler TR. Nutritional support in critical illness and recovery. Lancet Diabetes Endocrinol 2015;3:734-745.
6. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, McCarthy MS, Davanos E, Rice TW, Cresci GA, et al.; Society of Critical Care Medicine; American Society for Parenteral and Enteral Nutrition. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2016;40:159-211.
7. Unger RH. Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. Diabetes 1971;20:834-838.
8. Raskin P, Fujita Y, Unger RH. Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics. J Clin Invest 1975;56:1132-1138.
9. Gutniak M, Grill V, Efendić S. Effect of composition of mixed meals-low-versus high-carbohydrate content-on insulin, glucagon, and somatostatin release in healthy humans and in patients with NIDDM. Diabetes Care 1986;9:244-249.
10. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012; 122:4-12.
11. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol 2010;6:689-697.
12. Habegger KM, Stemmer K, Cheng C, Müller TD, Heppner KM, Ottaway N, Holland J, Hembree JL, Smiley D, Gelfanov V, et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013;62:1453-1463.
13. Rocha DM, Santeusanio F, Faloona GR, Unger RH. Abnormal pancreatic alpha-cell function in bacterial infections. N Engl J Med 1973;288:700-703.
14. Meguid MM, Brennan MF, Aoki TT, Muller WA, Ball MR, Moore FD. The role of insulin and glucagon in acute trauma. Surg Forum 1973;24: 97-98.
15. Orton CI, Segal AW, Bloom SR, Clarke J. Hypersecretion of glucagon and gastrin in severely burnt patients. BMJ 1975;2:170-172.
16. Wolfe RR, Burke JF. Somatostatin infusion inhibits glucose production in burn patients. Circ Shock 1982;9:521-527.
17. Wolfe RR, Shaw JH. Glucose and FFA kinetics in sepsis: role of glucagon and sympathetic nervous system activity. Am J Physiol 1985;248:E236-E243.
18. Jahoor F, Herndon DN, Wolfe RR. Role of insulin and glucagon in the response of glucose and alanine kinetics in burn-injured patients. J Clin Invest 1986;78:807-814.
19. Thiessen S, Vanhorebeek I, Derde S, Derese I, Dufour T, Nadège Albert C, Langouche L, Goossens C, Peersman N, Vermeersch P, et al. The role of glucagon during critical illness and its modulation by macronutrients. Poster presented at the 37th International Symposium on Intensive Care and Emergency Medicine. March 21-24, 2017, Brussels, Belgium.
20. Thiessen S, Vanhorebeek I, Derde S, Derese I, Dufour T, Nadège Albert C, Langouche L, Goossens C, Peersman N, Vermeersch P, et al. The role of glucagon during critical illness and its modulation by macronutrients. Poster presented at the Annual Meeting of the Endocrine Society. April 1-4, 2017, Orlando, FL.
21. Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, Van Cromphaut S, Ingels C, Meersseman P, Muller J, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011;365:506-517.
22. Marques M, Vander Perre S, Aertgeerts A, Derde S, Güiza F, Casaer MP, Hermans G, Van den Berghe G, Langouche L. Critical illness induces nutrient-independent adipogenesis and accumulation of alternatively activated tissue macrophages. Crit Care 2013;17:R193.
23. Brand CL, Rolin B, Jørgensen PN, Svendsen I, Kristensen JS, Holst JJ. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 1994;37:985-993.
24. Sørensen H, Brand CL, Neschen S, Holst JJ, Fosgerau K, Nishimura E, Shulman GI. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 2006;55:2843-2848.
25. Vamvini MT, Hamnvik OP, Sahin-Efe A, Gavrieli A, Dincer F, Farr OM, Mantzoros CS. Differential effects of oral and intravenous lipid administration on key molecules related to energy homeostasis. J Clin Endocrinol Metab 2016;101:1989-1997.
26. Sandoval DA, D'Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015;95: 513-548.
27. Goossens C, Marques MB, Derde S, Vander Perre S, Dufour T, Thiessen SE, Güiza F, Janssens T, Hermans G, Vanhorebeek I, et al. Premorbid obesity, but not nutrition, prevents critical illness-induced muscle wasting and weakness. J Cachexia Sarcopenia Muscle 2017; 8:89-101.
28. Wewer Albrechtsen NJ, Hartmann B, Veedfald S, Windeløv JA, Plamboeck A, Bojsen-Møller KN, Idorn T, Feldt-Rasmussen B, Knop FK, Vilsbøll T, et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 2014;57:1919-1926.
29. Friedrich O, Reid MB, Van den Berghe G, Vanhorebeek I, Hermans G, Rich MM, Larsson L. The sick and the weak: neuropathies/myopathies in the critically ill. Physiol Rev 2015;95: 1025-1109.
30. Lang CH, Bagby GJ, Blakesley HL, Spitzer JJ. Importance of hyperglucagonemia in eliciting the sepsis-induced increase in glucose production. Circ Shock 1989;29:181-191.
31. Samols E, Marri G, Marks V. Promotion of insulin secretion by glucagon. Lancet 1965;2:415-416.
32. Sinclair EM, Yusta B, Streutker C, Baggio LL, Koehler J, Charron MJ, Drucker DJ. Glucagon receptor signaling is essential for control of murine hepatocyte survival. Gastroenterology 2008; 135:2096-2106.
33. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 2003; 100:1438-1443.
34. Gu W, Yan H, Winters KA, Komorowski R, Vonderfecht S, Atangan L, Sivits G, Hill D, Yang J, Bi V, et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther 2009; 331:871-881.
35. Longuet C, Robledo AM, Dean ED, Dai C, Ali S, McGuinness I, de Chavez V, Vuguin PM, Charron MJ, Powers AC, et al. Liver-specific disruption of the murine glucagon receptor produces a-cell hyperplasia: evidence for a circulating a-cell growth factor. Diabetes 2013;62:1196-1205.
36. Solloway MJ, Madjidi A, Gu C, Eastham-Anderson J, Clarke HJ, Kljavin N, Zavala-Solorio J, Kates L, Friedman B, Brauer M, et al. Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of a-cell mass Cell Reports 2015;12:495-510.
37. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet 2009;373:1798-1807.
38. Deutschman CS, De Maio A, Clemens MG. Sepsis-induced attenuation of glucagon and 8-BrcAMP modulation of the phosphoenolpyruvate carboxykinase gene. Am J Physiol 1995;269:R584-R591.
39. Harp JB, Yancopoulos GD, Gromada J. Glucagon orchestrates stress-induced hyperglycaemia. Diabetes Obes Metab 2016;18:648-653.
40. Arvat E, Maccagno B, Ramunni J, Giordano R, DiVito L, Broglio F, Maccario M, Camanni F, Ghigo E. Glucagon is an ACTH secretagogue as effective as hCRH after intramuscolar administration while it is ineffective when given intravenously in normal subjects. Pituitary 2000;3:169-173.
41. Plomgaard P, Weigert C. Letter to the Editor: Comment on "FGF21 response to critical illness: effect of blood glucose control and relation with cellular stress and survival" by Thiessen S.E., et al. J Clin Endocrinol Metab 2015;100:L102-L103.
42. Liljenquist JE, Bomboy JD, Lewis SB, Sinclair-Smith BC, Felts PW, Lacy WW, Crofford OB, Liddle GW. Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. J Clin Invest 1974;53: 190-197.
43. Boden G, Rezvani I, Owen OE. Effects of glucagon on plasma amino acids. J Clin Invest 1984;73:785-793.
44. Charlton MR, Adey DB, Nair KS. Evidence for a catabolic role of glucagon during an amino acid load. J Clin Invest 1996;98:90-99.
45. Ginguay A, De Bandt JP, Cynober L Indications and contraindications for infusing specific amino acids (leucine, glutamine, arginine, citrulline, and taurine) in critical illness. Curr Opin Clin Nutr Metab Care 2016;19:161-169.
46. Gunst J, Vanhorebeek I, Casaer MP, Hermans G, Wouters PJ, Dubois J, Claes K, Schetz M, Van den Berghe G. Impact of early parenteral nutrition on metabolism and kidney injury. J Am Soc Nephrol 2013;24:995-1005.
47. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003;284:E671-E678.